Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuMax-CD4 (zanolimumab) in refractory or relapsed non-cutaneous CD4+ T-cell lymphoma
2004-000243-23Phase 2Completed
- Sponsor
- Genmab
- Start
- Jun 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanolimumab in peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), sponsored by Genmab. Primary endpoints: Objective tumor response at week 18 and Duration of tumor response. Started Jun 2004; status: completed.
02
Drugs
zanolimumab
03
Conditions
peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
Beyond the preview
Go deeper on 2004-000243-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000243-23.